

Respiratorius announces the filing of a new patent application in the USA

Respiratorius has filed a patent application that describes the preparation and use of a novel class of diazaheteroaryl bronchodilating low-molecular compounds with a potential use in asthma and COPD therapy. This drug-like class of bronchodilators has shown unprecedented potency and efficacy in ex-vivo tests using human lung tissue preparations in the Respiratorius proprietary tension measuring assay. Similar to Respiratorius previous families of bronchodilators, it shows a general and broad effect against multiple contractile agonists with a pronounced effect on the small airways. The efficacy on small human airways of Respiratorius compounds is greater than that of the clinically used beta-adrenergic agonist bronchodilators such as formoterol and salmeterol. Because Respiratorius' compounds have a demonstrated effect on human tissue, it is assumed that they will show clinical effect in humans. Dr. Martin Johansson, CSO, states that “our strategy of using a functional screening method with human tissue allows us to discover and optimize drug-like chemical lead structures very efficiently” and that “the filing of the latest patent application greatly strengthens our IP position and drug discovery pipeline”.

About Respiratorius

Respiratorius develops novel and effective pharmaceuticals to treat the common diseases chronic obstructive pulmonary disease (COPD) and severe asthma. The company's unique approach is based on new and patent-protected substances that, compared to existing therapies, are superior in relaxing the small human airways. The mechanism by which these substances act is novel, and they have been developed using Respiratorius world-leading, patent protected, force measuring equipment. Respiratorius was founded in 1999 as a spin-off from Lund University. Respiratorius AB is a public, privately owned company with more than 200 shareholders. Main investors include Fårö Capital, Staffan Rassjö, Mikael Lönn and Catella.

About Fårö Capital AB

Fårö Capital is an evergreen investor in Life Sciences, Design and Technology since 2000. Since inception Fårö Capital has invested in 10 companies with outstanding technology, management and market prospects. Some of the holdings include CellaVision, Flatfrog Laboratories, Agellis Group, Monkfish instruments, Respiratorius and EQL Pharma.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for a number of diseases that cause a limitation of airflow to the lungs and includes both permanent inflammation in the airways (chronic bronchitis) and emphysema. The conditions can occur independently from each other but the most common is to suffer from more than one. The sites of inflammation and irreversible airway obstruction are mainly in the small or peripheral airways.

Over time, the chronic inflammation and contraction causes permanent damage to the lungs which then lose their elasticity and in turn cause emphysema, where the alveoli have been damaged. This means that the lung function becomes chronically decreased and the patients obtain difficulty in breathing. Today there is no specific drug against COPD, but bronchodilators and anti-inflammatory therapies together with physical exercise in combination with changes in lifestyle, could help patients to handle their condition. COPD is the fourth most common cause of death in the world today, and in 2020 it is predicted to be the third most common cause of death.

In Sweden, it is calculated that approximately 500,000 people suffer from the disease and

every year about 2,000 people die as a result of COPD, which corresponds to 2% of all the deaths.

For further information, please contact:
Jörgen Gustafsson, CEO
+46 46 16 20 60
e-mail: jorgen.gustafsson@respiratorius.com